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In the present issue of Critical Care, Noveanu and 
colleagues evaluated brain natriuretic peptide (BNP) and 
N-terminal prohormone brain natriuretic peptide 
(NT-proBNP) serial measurements as predictive of 
30-day and 1-year mortality and readmission in patients 
admitted to the emergency department for acute decom-
pen  sated heart failure (ADHF) [1].
Th   e usefulness of measuring BNP and NT-proBNP in 
the diagnosis and management of congestive heart failure 
is well known [2,3]. Both BNP and NT-proBNP are useful 
for diagnosis in patients presenting with undiﬀ  erentiated 
dyspnoea in the emergency department and have been 
shown to accurately reﬂ   ect heart failure severity and 
prognosis [3-6]. Moreover, in some studies, serial BNP 
evaluations have been demonstrated to be useful in 
clinical management [7].
Noveanu and colleagues showed during 1-year follow-
up in a multivariate analysis that BNP at 24 hours (mean 
95% conﬁ  dence interval) (1.02 (1.01 to 1.04), P = 0.003), 
at 48 hours (1.04 (1.02 to 1.06), P <0.001) and at discharge 
(1.02 (1.01 to 1.03), P <0.001) independently predicted 
1-year mortality, while only predischarge NT-proBNP 
was predictive (1.07 (1.01 to 1.13), P = 0.016). Com  para-
ble results could be obtained for the secondary endpoint 
of 30-day mortality but not for 1-year heart failure 
readmissions.
Th   ese results from Noveanu and colleagues’ paper are 
in accordance with data reported by our group [8]. We 
demonstrated that a reduction of BNP >46% at hospital 
discharge coupled with a BNP absolute value <300 pg/ml 
resulted in a very powerful negative prognostic value for 
future cardiovascular outcomes in patients hospitalised 
with ADHF [8].
Other studies demonstrated the usefulness of repeated 
measurements of natriuretic peptides during hospitalisa-
tion in predicting survival of ADHF patients [8-11]. BNP 
variations during hospitalisation could give prognostic 
information, particularly at discharge, and could also 
suggest a qualitative variation of treatment (intensiﬁ  ca-
tion or decrement of drugs) on the basis of natriuretic 
peptide levels.
Noveanu and colleagues have also demonstrated that 
the prognostic accuracy of BNP was comparable at 
24  hours with 48 hours and with discharge [1]. Th  e 
authors suggested that BNP at 24 hours could be suitable 
to assess prognosis and to vary treatment in order to 
decrease mortality in patients with constant elevated 
levels of BNP. Th   is suggestion is in accordance again with 
data from our laboratory, where we showed that a drop of 
BNP >25% at 24 hours was a strong negative prognostic 
factor for future cardiovascular events [8], suggesting 
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most important causes of hospitalisation worldwide. 
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the diagnosis and management of heart failure. Their 
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their BNP >25% at 24 hours.
Rapid change in BNP levels seems to reﬂ  ect  an 
adequate response to heart failure therapy, and could be 
considered very important for early risk stratiﬁ  cation and 
therapy guidance. A lack of this response, assuming 
optimal medical treat  ment, implies a more complex and 
therapy-refractory disease, associated with an adverse 
long-term outcome. Accordingly, if this change in BNP 
level does not occur, treatment intensiﬁ  cation should be 
the consequence. In patients with a comparable decrease in 
BNP levels (roughly 30% between admission and 24 hours), 
we would expect a favourable outcome; however, future 
prospective studies need to evaluate a distinct cut-oﬀ   point 
to allow more precise recommendations [12].
Moreover, from the data of Noveanu and colleagues, 
BNP and NT-proBNP seem to show a diﬀ  erent response 
to treatment due to their diﬀ  erent kinetics. Th  is diﬀ  er-
ence is probably due to the slower decrease of NT-proBNP 
during treatment in ADHF patients in comparison with 
BNP [9-12]. Compared with NT-proBNP, BNP could be 
more useful to determine initial clinical stabilisation of 
ADHF patients, and to assess clinical improvement in 
hospitali  sation as we also demonstrated [13]. NT-proBNP 
could be used to assess initial diagnosis but is of limited 
help for repeat measurements during hospitalisation 
because its variations are not as sensitive and rapid as 
those of BNP [9-12,14].
In conclusion, in patients admitted to the emergency 
department for ADHF, serial measurements of BNP and 
NT-proBNP are useful because they show a similar 
powerful predictive role for mortality in the short term 
and in the long term. Interestingly, patients’ BNP and 
NT-proBNP varia  tions could help the physician to vary 
the thera  peutic approach during the initial hours of 
hospitalisation in order to obtain favourable outcomes.
Nevertheless, when considering hospital readmissions 
after discharge it seems that the variation of the two bio-
markers during hospitalisation at various time points is 
of no utility. Logeart and colleagues showed that only 
predischarge BNP was a strong predictor of death, and 
also of readmissions for heart failure with a cut-oﬀ   point 
of 350 ng/ml [10]. Previously published studies presum-
ing this ﬁ  nding – including Cheng and colleagues using 
BNP [15] or Bettencourt and colleagues using 
NT-proBNP [16] – used combined endpoints consisting 
of all-cause mortality and readmission for heart failure.
Although the results of Noveanu and colleagues’ study 
are to be considered of importance for the role of 
natriuretic peptides in prognostic stratiﬁ  cation for patients 
with ADHF, multicentre studies on a larger number of 
patients should be carried out to better elucidate the real 
value of natriuretic peptides in avoiding readmission after 
hospital discharge in heart failure patients.
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